Arianna Marinello, MD

74 posts

Arianna Marinello, MD banner
Arianna Marinello, MD

Arianna Marinello, MD

@AriMarinel

Medical oncologist at Gustave Roussy & PhD student at Université Paris-Saclay Precision medicine for lung cancer✨ Cellular therapy and innovative treatments ☀️

Paris, France Katılım Ocak 2022
353 Takip Edilen439 Takipçiler
Arianna Marinello, MD retweetledi
Benjamin Besse
Benjamin Besse@BenjaminBesseMD·
Be ready to screen MTAP loss in all pts with advanced NSCLC, regardless of driver. @mihaela_aldea shows incidence, highest in ALK/RET/EGFR/ROS1. AMG193 paved the way at #ESMO24. BMS-986504 confirms druggability: 29% ORR + many durable SD (slide @CharuAggarwalMD). #WCLC25
Benjamin Besse tweet mediaBenjamin Besse tweet mediaBenjamin Besse tweet media
English
5
40
119
9.5K
Arianna Marinello, MD
Arianna Marinello, MD@AriMarinel·
Excited to share our article out in @JAMAOnc The first to report the expression of membrane targets in RET+ NSCLC in a wide international cohort Have a look: jamanetwork.com/journals/jamao… @GustaveRoussy @CarisLife
Arianna Marinello, MD tweet media
Mihaela Aldea@mihaela_aldea

🚨 New insights in #RETpositive #LungCancer: RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2. ➡️ Multiple membrane targets may co-exist 🧬 Dynamic changes post-treatment — fresh biopsy recommended 💡 Supports ADC & bispecific antibody trials #JamaOncol @RETpositive @AriMarinel @GustaveRoussy @CarisLife jamanetwork.com/journals/jamao…

English
0
6
23
1.3K
Arianna Marinello, MD
Arianna Marinello, MD@AriMarinel·
So grateful for the great opportunity to participate to @IASLC Academy this year!
Arianna Marinello, MD tweet media
English
3
0
16
558
Arianna Marinello, MD retweetledi
Alessandro Russo
Alessandro Russo@Al3ssandroRusso·
The use of liquid biopsy can allow a better selection of NSCLC patients candidate to IO or Chemo-IO. Very interesting data, further confirming the prognostic role of Tumor Fraction at baseline @isliquidbiopsy @ChristianRolfo Congrats @FilippoDallOlio and team!
Filippo Dall'Olio@FilippoDallOlio

Can #liquidbiopsy (#tumorfraction) help identify #NSCLC patients who respond better to chemo-immunotherapy vs those who benefit from the low toxicity of single-agent immunotherapy? Pushing boundaries in #precisiononcology @GustaveRoussy @FoundationATCG @BenjaminBesseMD @myESMO

English
1
13
25
1.6K
Arianna Marinello, MD retweetledi
Filippo Dall'Olio
Filippo Dall'Olio@FilippoDallOlio·
What happens in the tumor and in the host when tumor burden increases? Could we use tMTV to decide when intensify the treatment in aNSCLC? We tried to answer these questions in our multicentric effort @BenjaminBesseMD @GustaveRoussy
Benjamin Besse@BenjaminBesseMD

ICB or chemo-ICB in PD-L1≥50% advanced NSCLC? Metabolic tumor volume (tMTV) assessed by 18F FDG petscan can guide you. High tMTV lesions might have a different biology and be better candidate to chemo-ICB. @FilippoDallOlio aacrjournals.org/clincancerres/…

Vorst, België 🇧🇪 English
0
2
7
708
Arianna Marinello, MD retweetledi
Gustave Roussy
Gustave Roussy@GustaveRoussy·
🏆 Un grand bravo à Dr Antonio di Meglio, Dr Cédric Pobel, Dr Adèle Bonato, Dr Adrien Rousseau, Dr Arianna Marinello pour le prix du "Merit Travel Grant" de l'#ESMO24.
Gustave Roussy tweet media
Français
0
7
42
2.3K
Arianna Marinello, MD retweetledi
Gustave Roussy
Gustave Roussy@GustaveRoussy·
🔹@GustaveRoussy à l'#ESMO24 Les experts de l'institut sont présents pour leurs sessions poster. 💪 Mora Guardanamie, Arianna Marinello et Mihaela Aldea, Adrien Rousseau et Filippo Dall’Olio. ⤵
Gustave Roussy tweet mediaGustave Roussy tweet mediaGustave Roussy tweet mediaGustave Roussy tweet media
Français
1
8
28
2.4K
Arianna Marinello, MD retweetledi
Lodovica Zullo
Lodovica Zullo@LodovicaZullo·
From the largest RET-registry, a huge multicentric effort, @AriMarinel presents outcomes to inhibitors/chemo in RET+ advanced NSCLC according to histological subtypes. @GustaveRoussy @myESMO
Lodovica Zullo tweet media
English
0
3
31
1K
Arianna Marinello, MD
Arianna Marinello, MD@AriMarinel·
The time for a practice-changing trial in locally advanced SCLC has come! 🏆 In the ADRIATIC trial: significant OS benefit with durvalumab consolidation versus placebo after CTRT: - 55.9 versus 33.4 months OS at the first interim analysis #ASCO24
Arianna Marinello, MD tweet media
English
0
2
6
509
Arianna Marinello, MD
Arianna Marinello, MD@AriMarinel·
One-minute applause and standing ovation for the PFS LAURA in today plenary session at #ASCO24 🏆 Consolidation therapy with osimertinib in unresectable stage III NSCLC improves PFS with an outstanding HR of 0.16 What a great time to cure lung cancer patients!
Arianna Marinello, MD tweet mediaArianna Marinello, MD tweet mediaArianna Marinello, MD tweet media
English
0
1
5
314
Arianna Marinello, MD retweetledi
FabriceAndre
FabriceAndre@FAndreMD·
We know how will be the next Research Building @GustaveRoussy (Q1 2027) 32 000 m2 , 60 research teams in 15 Centers, 15 core facilities, 1400 staff. Each floor will include 10 teams of biology that will surround Data Science / Epidemiology teams. We are welcoming new teams !
FabriceAndre tweet mediaFabriceAndre tweet mediaFabriceAndre tweet mediaFabriceAndre tweet media
English
6
14
154
59.6K
Arianna Marinello, MD retweetledi
Benjamin Besse
Benjamin Besse@BenjaminBesseMD·
Ceralasertib (ATR kinase inhibitor) for 7 days + durvalumab q4w: a promising combo post chemo-IO in pts with advanced NSCLC! nature.com/articles/s4159…. Benefit seen in all comers, including ATM altered NSCLC & manageable safety. Currently tested vs docetaxel in the trial Latify.
English
1
34
101
7.2K
Arianna Marinello, MD retweetledi
ESMO - Eur. Oncology
ESMO - Eur. Oncology@myESMO·
ESMO Guideline: Oncogene-Addicted #mNSCLC. Developed due 2 advances in biomarker identificatn & targeted therapies; updated recommendatns & tx algorithms on new & clinically relevant biomarker identificatn, targeting & adv disease managemt.ow.ly/b89e50QkVFs @Annals_Oncology
ESMO - Eur. Oncology tweet media
English
3
75
156
18.2K
Arianna Marinello, MD retweetledi
Jordi Remon
Jordi Remon@JordiRemon·
We’ll start 2024 with this ttx algorithm for NSCLC🫁including non-metastatic NSCLC Pending Qx💡: ✏️Will ADC overcome docetaxel? 📛 ✏️ADC 2n L for oncogenic-driven? 🎉 ✏️Perioperative vs Induction?🥊 ✏️Adjuvant RET TKI?🧬 ✏️Academic trials for ↗️ / ↘️ ttx And more!! @oncoalert
Jordi Remon tweet media
English
8
73
184
12.3K
Arianna Marinello, MD
Arianna Marinello, MD@AriMarinel·
Incredibily amazing discussion conducted by @BenjaminBesseMDtk conclude this exciting plenary session on #NSCLC with rare alterations -> The (un)necessary trials So proud of being part of his motivated team!
Arianna Marinello, MD tweet media
Madrid, Spain 🇪🇸 English
0
0
9
217

Keşfet

@mihaela_aldea @CharuAggarwalMD @RobertoFerrara_ @Max_Cani @Gmazzaschi90 @pecci_federica1 @doctordegio @CarloGenova5